EVOTEC AG (FRA:EVT) Evotec AG (EVT-DE): Innovating for the long term

Transparency directive : regulatory news

14/12/2018 16:29

goetzpartners securities Limited
Evotec AG (EVT-DE): Innovating for the long term

14-Dec-2018 / 15:29 GMT/BST

Free to access research and investor meetings in a post-MiFID2 world.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

Published to the market and investors on 14th December 2018 @ 8.08am (GMT).


Evotec AG (EVT-DE): Innovating for the long term
Recommendation: OUTPERFORM
Target Price: EUR25.00
Current Price: EUR18.46 (CoB on 13th December 2018)


We have updated our model following 9M/2018 results and reiterate our sum-of-the-part ("SoTP") derived target price ("TP") of EUR25/share (>30% upside). Our 2018E and 2019E estimates are slightly above consensus and we expect Evotec to comfortably exceed 2018 outlook. Evotec is a structural growth story for many years to come, based on four key drivers, in our view: (1) Continued strong outsourcing trend from pharma and biotech in line with the macro trend for external innovation, (2) further consolidation in the highly fragmented CRO industry, (3) substantial upside from its co-owned pipeline, the value of which grows as more projects are added and advance through clinical development, and (4) investments into cutting-edge technologies to remain at the forefront of innovation in drug discovery and beyond. We maintain and reiterate our OUTPERFORM recommendation.

On track to comfortably exceed 2018 financial outlook

Evotec's 2018 financial performance has been very strong. Robust organic growth was boosted by Aptuit, which accounted for two-thirds of the 57% revenue growth in 9M/2018. The Execute business grew by 53% in 9M2018 and the Innovate business by 55%, aided by significant (highly profitable) milestone income, including c.EUR14m from iPSC deals. For FY2018E, we forecast revenue and adjusted EBITDA growth of +41% and 55% YoY, respectively, comfortably above company outlook of >30% and c.30%. To put our estimates into context, we note that: (1) our Q4 revenue forecast is in line with Q2 and Q3; (2) Evotec would only need to generate adjusted EBITDA of c.EUR7m in Q4 (vs. EUR23m on average in each previous 2018 quarter) to achieve its target.

Innovation leadership and co-owned pipeline are key value drivers

While we expect Evotec to continue benefiting from the overall favourable CRO industry dynamics, it is the company's innovation leadership and ability to implement this into the service offering (Execute) and partnership agreements (Innovate) that will drive the most share price upside in the longer term, in our view. This is best exemplified through Evotec's global leadership in induced pluripotent stem cell ("iPSC") technology, which has the potential to revolutionise early-stage drug development, and the use of artificial intelligence ("AI") and machine learning tools in the discovery process. The latter should reduce the costs and duration of drug discovery whilst increasing the probability of success. AI is already being used in drug design and synthetic processes.

SoTP valuation highlights long-term upside from EVT Innovate and iPSC platform

We value Evotec using a SoTP analysis that consists of net present values for EVT Execute, EVT Innovate excl. iPSC, the iPSC platform, net cash at YE2019E, and future M&A deals, which account for approx. one-third of our TP. The inclusion of an M&A component is justified on the basis that Evotec has been able to significantly expand through the successful acquisition of highly complementary businesses, such as Cyprotex, Aptuit, and the former Sanofi R&D sites in Toulouse and Lyon.

Kind regards,

Brigitte de Lima | Analyst

goetzpartners Healthcare Research Team | Research Team

goetzpartners securities Limited

The Stanley Building, 7 Pancras Square, London, N1C 4AG, England, UK.

T +44 (0) 203 859 7725 | brigitte.delima@goetzpartners.com / healthcareresearch@goetzpartners.com


Registered in England No. 04684144.

Managing Directors: Dr Stephan Goetz, Martin Brunninger and Ulrich Kinzel.

goetzpartners securities Limited - Team Members

Equity Research Analysts - Martin Brunninger, Brigitte de Lima, Chris Redhead and Martin Piehlmeier.

Sales / Marketing - Erland Sternby.

Corporate Finance - Ulrich Kinzel, Wolf Dornbusch and Youchen Xin.

Corporate Access and IR - Tanya Tracey and Bettina Ellinghorst.

Compliance - Paul W. Dunne.

Click here to see our privacy policy.

GPSL has a formal client relationship with Evotec AG.

GPSL publishes and distributes "Investment" Research and "Corporate Sponsored" Research. Our Corporate Sponsored Research and investor meetings (e.g. NDRs, 1 to 1 meetings) are free to access and attend and is not classified as an inducement in a post-MiFID2 world, this is because the issuer is paying GPSL. GPSL does not offer any execution or market making services. This is a marketing communication as defined by the Financial Conduct Authority ("FCA"). The information herein is considered to be an acceptable minor non-monetary benefit as defined under FCA COBS 2.3A19(5).

In accordance with the General Data Protection Regulation ("GDPR") - if you would like to be removed / unsubscribed from our CRM (also please note that you are free to contact GPSL at any time in the future to have your e-mail subscription amended), please e-mail:

About GPSL: goetzpartners securities Limited is a member of the goetzpartners group, and a leading pan European investment bank and research company. We bring together a wide range of expertise, insights and innovations to advance the interests of our clients around the world. The fast-changing environment brings challenges for businesses and investors. Research innovation, digital transformation and disruptive business ideas reshuffle the corporate world at a relentless pace. Our sector knowledge and our global footprint bring together corporate intelligence and a deep understanding of the industry with a wide network of top decision makers. These collective insights help our clients to stay at the leading edge of change.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

This communication (including any attachments) from goetzpartners securities Limited ("GPSL") is confidential and may contain information which is proprietary, privileged or otherwise legally protected against unauthorised use or disclosure. If you receive this communication in error or are not the intended recipient of this communication, please delete and destroy all copies in your possession, notify the sender that you have received this communication, and note that any review or dissemination of, or the taking of any action in reliance on this communication is expressly prohibited. GPSL shall not be liable for the improper or incomplete transmission of the information contained in this communication nor for any delay in its receipt or damage to your system. GPSL does not guarantee that the integrity of this communication has been maintained nor that this communication is free of viruses, interceptions or interference and makes no warranties in relation to these matters. This is not an offer or a solicitation to buy or sell securities or investment products, or an official confirmation. GPSL record electronic and phone communications in accordance with FCA and MiFID2 regulations, they will be monitored for regulatory and training purposes. GPSL is authorised and regulated by the Financial Conduct Authority of the United Kingdom (Firm Reference Number: 225563).

Click on the following link for the GPSL MiFID2 Investor Guidance Notice

GPSL Equity Research publications are available on the following aggregators and via news distribution circuits (For Institutional Use Only): AlphaMetry, AlphaSense, Bloomberg (GOET), Capital IQ, EQS, FACTSET, ResearchFN, Research Tree, RNS Reach, Sentieo and Thomson Reuters.

Please copy the below link and paste it into your browser for the full pdf version of the equity research report:


Free to access research and investor meetings in a post-MiFID2 world.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

End of Announcement - EQS News Service

758587  14-Dec-2018 


Other stories

24/01/2020 14:38
24/01/2020 13:36
24/01/2020 12:27
24/01/2020 10:56
24/01/2020 00:05
24/01/2020 12:30
24/01/2020 14:16
24/01/2020 13:04
24/01/2020 14:32
24/01/2020 02:37
24/01/2020 10:14
24/01/2020 14:07
24/01/2020 10:54
24/01/2020 14:00
24/01/2020 11:46
24/01/2020 10:25
24/01/2020 11:51
24/01/2020 10:32
24/01/2020 11:31
24/01/2020 11:21
24/01/2020 14:25
24/01/2020 11:00
24/01/2020 05:47
24/01/2020 14:09
24/01/2020 12:04
24/01/2020 15:04
24/01/2020 10:25
24/01/2020 15:01
24/01/2020 09:29
24/01/2020 12:31
23/01/2020 22:30
24/01/2020 13:00
24/01/2020 09:04
23/01/2020 17:05
24/01/2020 14:21
23/01/2020 20:25
22/01/2020 15:37
23/01/2020 10:50